The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration
The aim of this study was to measure serum and mucosal antibody responses following intranasal administration of biodegradable poly(dl-lactide-co-glycolide) (PLGA) microspheres loaded with the CS3 colonization factor isolated from enterotoxigenic Escherichia coli (ETEC). The response was compared against that measured in mice similarly administered the native CS3 antigen and in mice co-administered, along with the CS3 antigen, a known mucosal adjuvant, the R192G mutant heat-labile enterotoxin (mLT). The integrity of the CS3 antigen released from the microspheres was maintained as determined by SDS-PAGE and immunoblotting. Native CS3 induced serum and mucosal (bronchoalveolar, small intestinal and faecal) IgG and IgA responses. The co-administration of the mLT mucosal adjuvant significantly enhanced (P<0·001) serum and mucosal antibody responses to the CS3 protein. Likewise, the CS3-loaded PLGA microspheres induced significantly greater (P<0·001) serum and mucosal antibody responses than native CS3, as well as inducing antibody responses superior to those of the CS3 plus mLT formulation. Following administration of CS3 plus mLT, the mice became distressed (loss of activity, increased huddling, ruffled fur), a situation not seen following administration of the CS3-loaded PLGA microspheres. The results in this trial show that the CS3-loaded PLGA microspheres when administered intranasally to mice caused no observable distress to the mice and significantly (P<0·001) enhanced the immunogenicity of the CS3 protein.
AlvesA. M. B, LásaroM. O,
AlmeidaD. F, FerreiraL. C. S.
1998; Immunoglobulin G subclass responses in mice immunized with plasmid DNA encoding the CFA/I fimbria of enterotoxigenic Escherichia coli . Immunol Lett 62:145–149[CrossRef]
BeignonA.-S, BriandJ.-P, RappuoliR, MullerS, PartidosC. D.
2002; The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4[sup]+[/sup] T cells and secrete gamma interferon after coapplication onto bare skin. Infect Immun 70:3012–3019[CrossRef]
BoyakaP. N, OhmuraM, FujihashiK.
& 8 other authors; 2003; Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanicity and direct Th cell subsets via their B subunit. J Immunol 170:454–462[CrossRef]
ByrdW, CasselsF. J.
2003; Mucosal immunization of BALB/c mice using enterotoxigenic Escherichia coli colonization factors CFA/I and CS6 administered with and without a mutant heat-labile enterotoxin. Vaccine 21:1884–1893[CrossRef]
ByrdW, de LorimierA, ZhengZ.-R, CasselsF. J.
2005; Microencapsulated subunit vaccine approach to enterotoxigenic Escherichia coli and other mucosal pathogens. Adv Drug Del Rev 57:1362–1380[CrossRef]
CoyleA. J, WagnerK, BertrandC, TsuyukiS, BewsJ, HeusserC.
1996; Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 183:1303–1310[CrossRef]
EldridgeJ. H, StaasJ. K, MeulbroekJ. A, TiceT. R, GilleyR. M.
1991b; Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59:2978–2986
EylesJ. E, SpiersI. D, WilliamsonE. D, AlparH. O.
1998a; Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines. Vaccine 16:2000–2009[CrossRef]
EylesJ. E, SharpG. J. E, WilliamsonE. D, SpiersI. D, AlparH. O.
1998b; Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plaque in the mouse. Vaccine 16:698–707[CrossRef]
EylesJ. E, WilliamsonE. D, SpiersI. D, AlparH. O.
2000; Protection studies following bronchopulmonary and intramuscular immunization with Yersinis pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine 18:3266–3271[CrossRef]
HeritageP. L, UnderdownB. J, ArsenaultA. L, SniderD. P, McDermottM. R.
1997; Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am J Respir Crit Care Med 156:1256–1262[CrossRef]
HodgeL. M, MarinaroM, JonesH. P, McGheeJ. R, KiyonoH, SimeckaJ. W.
2001; Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect Immun 69:2328–2338[CrossRef]
HyamsK. C, BourgeoisA. L, MerrellB. R.
& 9 other authors (1991). Diarrheal disease during Operation Desert Shield. N Engl J Med 325:1423–1428[CrossRef]
JonesD. H.
2003; Microencapsulation of vaccine antigens. In Methods in Molecular Medicine, vol. 87, Vaccine Protocols pp 211–222 Edited by
RobinsonA.,
HudsonM. J., CranageM. P.
Totowa, NJ: Humana Press;
KerstenG. F. A, GanderB.
1996; Biodegradable microspheres as vehicles for antigens. In Concepts in Vaccine Development pp 265–302 Edited by
KaufmannS. H. E.
Berlin: Walter de Gruyter;
KilianM, MesteckyJ, RussellM. W.
1988; Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev 52:296–303
KiyonoH, BienenstockJ, McGheeJ. R, ErnstP. B.
1992; The mucosal immune system: features of inductive and effector sites to consider in mucosal immunization and vaccine development. Reg Immunol 4:54–62
LewisD. H.
1990; Controlled release of bioactive agents from lactide/glycolide polymers. In Biodegradable Polymers as Drug Delivery Systems pp 1–41 Edited by
ChasinM.,
LangerR.
New York: Marcel Dekker;
ManzanecM. B, LammM. E, LynD, PortnerA, NedrudJ. G.
1992; Comparison of IgA versus IgG monoclonal antibodies for passive immunisation of the murine respiratory tract. Virus Res 23:1–12[CrossRef]
McGeeJ. P, DavisS. S, O’HaganD. T.
1994; The immunogenicity of a model protein entrapped in poly(lactide-co-glycolide) microparticles prepared by a novel phase separation technique. J Control Release 31:55–60[CrossRef]
PierceN. F, ReynoldsH. Y.
1974; Immunity to experimental cholera: I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J Immunol 113:1017–1023
RobbinsJ. B, ChuC, SchneersonR.
1992; Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 15:346–361[CrossRef]
RobbinsJ. B, SchneersonR, SzuS. C.
1995; Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171:1387–1398[CrossRef]
RobbinsJ. B, SchneersonR, SzuS. C.
1997; O-specific polysaccharide-protein conjugates for prevention of enteric bacterial diseases. In New Generation Vaccines pp 803–815 Edited by
LevinM. M.,
WoodrowG. C.,
KaperJ. B., CobonG. S.
New York: Marcel Dekker;
RudinA, JohanssonE.-L, BergquistC, HolmgrenJ.
1998; Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun 66:3390–3396
SasiakA. B, BolgianoB, CraneD. T, HockleyD. J, CorbelM. J, SesardicD.
2001; Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines. Vaccine 19:694–705
ZuberiR. I, ApgarJ. R, ChenS.-S, LiuF.-T.
2000; Role for IgE in airway secretions: IgE immune complexes are more potent inducers than antigen alone of airway inflammation in a murine model. J Immunol 164:2667–2673[CrossRef]
The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration